Atossa Therapeutics, Inc. (ATOS) Financial Statements (2024 and earlier)

Company Profile

Business Address 107 SPRING STREET
SEATTLE, WA 98104
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments110,890,000136,377,00039,553,67112,581,13610,380,4937,217,469
Cash and cash equivalents110,890,000136,377,00039,553,67112,581,13610,380,4937,217,469
Restricted cash and investments110,000110,000110,000110,000110,00055,000
Receivables      358,277
Prepaid expense4,031,0002,488,0001,813,902862,344509,833250,944
Other current assets2,423,0001,193,000657,66226,13030,94216,344
Other undisclosed current assets743,0001,072,000634,940739,656518,098 
Total current assets:118,197,000141,240,00042,770,17514,319,26611,549,3667,898,034
Noncurrent Assets
Operating lease, right-of-use asset   18,05350,479
Property, plant and equipment  20,00020,63234,35054,48711,467
Intangible assets, net (including goodwill)      75,686
Intangible assets, net (excluding goodwill)      75,686
Other noncurrent assets635,0002,00017,21817,21817,218178,907
Other undisclosed noncurrent assets4,700,000 13,37568,54299,375 
Total noncurrent assets:5,335,00022,00069,278170,589171,080266,060
TOTAL ASSETS:123,532,000141,262,00042,839,45314,489,85511,720,4468,164,094
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,024,0003,105,0002,645,6451,270,4791,465,4721,209,873
Employee-related liabilities1,184,000963,665899,420935,070784,867
Accounts payable2,965,0001,717,0001,588,613293,171353,328334,901
Accrued liabilities1,059,000204,00093,36777,888177,07490,105
Debt    39,371  
Deferred compensation liability     1,410,025 
Other liabilities19,00021,0004,74812,89239,93915,534
Other undisclosed current liabilities1,525,000 13,021,128   
Total current liabilities:5,568,0003,126,00015,671,5211,322,7422,915,4361,225,407
Noncurrent Liabilities
Long-term debt and lease obligation:    11,108  
Operating lease, liability    11,108
Total noncurrent liabilities:    11,108  
Total liabilities:5,568,0003,126,00015,671,5211,333,8502,915,4361,225,407
Equity
Equity, attributable to parent, including:117,964,000138,136,00027,167,93213,156,0058,805,0106,938,687
Preferred stock   112 
Common stock22,792,00022,792,0008,558,7781,643,5651,052,372477,342
Treasury stock, value      
Additional paid in capital250,784,000243,996,000129,887,146105,583,47984,583,89971,887,674
Accumulated deficit(156,194,000)(129,234,000)(111,898,992)(94,071,040)(76,831,263)(65,426,329)
Other undisclosed equity, attributable to parent582,000582,000620,999   
Total equity:117,964,000138,136,00027,167,93213,156,0058,805,0106,938,687
TOTAL LIABILITIES AND EQUITY:123,532,000141,262,00042,839,45314,489,85511,720,4468,164,094

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(27,691,000)(20,521,000)(14,607,392)(17,265,425)(11,434,233)(7,649,171)
Operating loss:(27,691,000)(20,521,000)(14,607,392)(17,265,425)(11,434,233)(7,649,171)
Nonoperating income (expense)731,000(85,000)50,80125,64829,299154
Investment income, nonoperating877,000    (17,695)
Other nonoperating income (expense)(146,000)(85,000)50,80125,64829,299 
Interest and debt expense      (79,410)
Other undisclosed loss from continuing operations before equity method investments, income taxes      (394,154)
Loss from continuing operations before equity method investments, income taxes:(26,960,000)(20,606,000)(14,556,591)(17,239,777)(11,404,934)(8,122,581)
Other undisclosed loss from continuing operations before income taxes  (3,271,361)   
Loss from continuing operations:(26,960,000)(20,606,000)(17,827,952)(17,239,777)(11,404,934)(8,122,581)
Loss before gain (loss) on sale of properties:(20,606,000)(17,827,952)(17,239,777)(11,404,934)(8,122,581)
Net loss attributable to parent:(26,960,000)(20,606,000)(17,827,952)(17,239,777)(11,404,934)(8,122,581)
Preferred stock dividends and other adjustments      (2,568,132)
Other undisclosed net loss available to common stockholders, basic   (4,502,799) (11,479,308) 
Net loss available to common stockholders, diluted:(26,960,000)(20,606,000)(22,330,751)(17,239,777)(22,884,242)(10,690,713)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(26,960,000)(20,606,000)(17,827,952)(17,239,777)(11,404,934)(8,122,581)
Comprehensive loss:(26,960,000)(20,606,000)(17,827,952)(17,239,777)(11,404,934)(8,122,581)
Other undisclosed comprehensive income, net of tax, attributable to parent      
Comprehensive loss, net of tax, attributable to parent:(26,960,000)(20,606,000)(17,827,952)(17,239,777)(11,404,934)(8,122,581)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: